Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
AACR 2025 preview – new preclincal approaches abound
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Ideaya's conjugate journey continues
The synthetic lethality specialist licenses in its second ADC in six months.
